Ovarian Cancer Drugs Market Trends, Size, Growth by 2030
[Research Report] The ovarian cancer drugs market size is projected to grow from US$ 2.1 billion in 2022 to US$ 3.8 billion by 2030; the market is estimated to record a CAGR of 7.7% during 2022–2030.
Market Insights and Analyst View:
The rising incidence of ovarian cancer propels the ovarian cancer drugs market growth. However, product recalls due to adverse effects impede the market growth.
Growth Drivers:
Rising Incidence of Ovarian Cancer Propels Demand for Therapeutic Options
Ovarian cancer is the seventh most common cancer among women and the third most common gynecological malignancy, after cervical cancer and endometrial (uterine) cancers, respectively. According to the World Ovarian Cancer Coalition report, 324,000 women are diagnosed with ovarian cancer, and 207,000 women die of the disease annually. Further, the majority of patients with ovarian cancer are diagnosed with an advanced-stage (locally advanced or metastatic) condition as there is no public health screening program available for the early detection of ovarian cancer. Therefore, the rising incidence of ovarian cancer propels the demand for effective therapeutic options. The first-line therapy with a combination of debulking surgery and platinum-based chemotherapy is standard care for women newly diagnosed with advanced ovarian cancer. Also, therapeutic options such as approved PARP inhibitors, olaparib, rucaparib, and niraparib are the breakthrough options for the management of newly diagnosed ovarian cancer. The use of PARP inhibitors in the management of advanced ovarian cancer has also emerged as an effective therapeutic option to improve clinical outcomes. These inhibitors provide long-term efficacy and progression-free survival (PFS) in the newly diagnosed cases, following a complete response (CR) to the first, second, and third platinum-based chemotherapy.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Ovarian Cancer Drugs Market: Strategic Insights
Market Size Value in US$ 2.1 billion in 2022 Market Size Value by US$ 3.8 billion by 2030 Growth rate CAGR of 7.7% from 2022 to 2030 Forecast Period 2022-2030 Base Year 2022
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Ovarian Cancer Drugs Market: Strategic Insights
| Market Size Value in | US$ 2.1 billion in 2022 |
| Market Size Value by | US$ 3.8 billion by 2030 |
| Growth rate | CAGR of 7.7% from 2022 to 2030 |
| Forecast Period | 2022-2030 |
| Base Year | 2022 |
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Report Segmentation and Scope:
The ovarian cancer drugs market analysis has been carried out by considering the following segments: type, drug class, and distribution channel.
Segmental Analysis:
By type, the market is segmented into epithelial ovarian cancer, germ cell ovarian cancer, and stromal tumors. The epithelial ovarian cancer segment held the largest ovarian cancer drugs market share in 2022; the same segment is anticipated to register the highest CAGR of 8.2% during the forecast period. According to the Cancer Research UK report, epithelial ovarian cancer is the most common type of ovarian cancer. For example, nearly 90 out of 100 tumors of the ovary (90%) are epithelial tumors. Patients with aggressive, late-stage ovarian cancer have limited treatment options available in the market. In November 2022, the Food and Drug Administration (FDA) announced approval for "mirvetuximab soravtansine-gynx," manufactured by Elahere ImmunoGen, Inc. for adult patients suffering from epithelial ovarian cancer. The physician-recommended dose of this drug candidate for epithelial ovarian cancer treatment is 6 mg/kg, administered once every three weeks as an IV infusion. In January 2024, the FDA announced approval for fast-track designation (FTD) for "RC88," a mesothelin-targeting antibody-drug conjugate (ADC) for the treatment of patients with recurrent epithelial ovarian cancer. Thus, the rising number of drug approvals is propelling the ovarian cancer drugs market for the epithelial ovarian cancer segment.
Ovarian Cancer Drugs Market Trends
Combination Drug Therapy
Several medical research institutes are developing novel combination drugs to treat ovarian cancers. In September 2023, researchers at the Royal Marsden announced a new drug combination therapy that proves effective in patients living with advanced ovarian cancer. The researchers tested combination drug therapy for its effect on low-grade serous ovarian cancer (LGSOC), a rare form of ovarian cancer with a poor response rate to treatments. The RAMP-201 clinical trial was conducted by combining the avutometinib drug with defactinib to investigate their synergistic therapeutic effect in patients suffering from LGSOC. The interim clinical trial results reveal that 45% of the patients treated with the drug combination saw their tumors shrink significantly. Such satisfactory clinical results with combination therapy are almost twice as effective compared to trametinib, a targeted therapy drug available in England that has a response rate of only 26%. In January 2024, the FDA announced approval for the SH-105 combination drug for the treatment of patients with breast and ovarian cancer. Thus, combination drug therapies are emerging as new trends that are likely to boost the ovarian cancer drugs market growth in the coming years.
Regional Analysis:
The scope of the ovarian cancer drugs market report entails North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In 2022, North America held the largest ovarian cancer drugs market share. The market growth in this region is driven by the increasing number of product launches by top companies and the presence of key market players. The US is the largest contributor to the market in North America. The rising incidence of ovarian cancers among women compels companies and regulatory bodies to develop and approve, respectively, innovative drugs in this region. Also, the rising number of contract clinical research organizations (CROs) favors the growth of the ovarian cancer drugs market in North America.
Ovarian Cancer Drugs Market Report Scope
Industry Developments and Future Opportunities:
The ovarian cancer drugs market forecast can help stakeholders in this marketplace plan their growth strategies. A few strategic developments by leading players operating in the market are listed below:
- In November 2022, ImmunoGen won FDA approval for ELAHERE (mirvetuximab soravtansine-gynx) for the treatment of adult patients resistant to platinum-resistant epithelial ovarian cancer. The ELAHERE is specifically approved for patients with FRα-positive platinum-resistant ovarian cancer, which is a challenging condition due to the availability of limited treatment options and poor clinical outcomes of the existing therapeutics.
Competitive Landscape and Key Companies:
Elli Lilly, AstraZeneca, GSK, Zielab, ImmunoGen (AbbVie), GeneTech (Roche), Vivesto, Allarity Therapeutics, Inc., Aeterna Zentaris, and Luye Pharma are among the prominent companies profiled in the ovarian cancer drugs market report. These companies focus on developing new technologies, upgrading existing products, and expanding their geographic presence to meet the growing consumer demand worldwide.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Type, Drug Class, Distribution Channel, and Geography
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The CAGR value of the ovarian cancer drugs market during the forecasted period of 2022-2030 is 7.7%.
The epithelial ovarian cancer segment held the largest share of the market in the global ovarian cancer drugs market and held the largest market share in 2022.
Ovarian cancer is a growth of cells that is formed in the ovaries where the cells can multiply quickly and invade destroying the healthy body tissues. Therefore, rising prevalence of ovarian cancer among women enhances therapeutic option and drugs.
The PARP inhibitors segment dominated the global ovarian cancer drugs market and held the largest market share in 2022.
The ovarian cancer drugs market majorly consists of the players such Elli Lilly, AstraZeneca, GSK, Zielab, ImmunoGen (AbbVie), GeneTech (Roche), Vivesto, Allarity Therapeutics, Inc., Aeterna Zentaris, and Luye Pharma, and amongst others.
Global ovarian cancer drugs market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa and South & Central America. North America held the largest market share of the ovarian cancer drugs market in 2022.
Elli Lilly and GeneTech (Roche) are the top two companies that hold huge market shares in the ovarian cancer drugs market.
1. Introduction
1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 Market Attractiveness Analysis
3. Research Methodology
4. Ovarian Cancer Drugs Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
4.3.1 List of Vendors in the Value Chain
5. Ovarian Cancer Drugs Market - Key Market Dynamics
5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints
6. Ovarian Cancer Drugs Market - Global Market Analysis
6.1 Ovarian Cancer Drugs - Global Market Overview
6.2 Ovarian Cancer Drugs - Global Market and Forecast to 2031
7. Ovarian Cancer Drugs Market – Revenue Analysis (USD Million) – By Type, 2021-2031
7.1 Overview
7.2 Epithelial Ovarian Cancer
7.3 Germ Cell Ovarian Cancer
7.4 Stromal Tumors
8. Ovarian Cancer Drugs Market – Revenue Analysis (USD Million) – By Drug Class, 2021-2031
8.1 Overview
8.2 PARP Inhibitors
8.3 Anti-Angiogenesis Inhibitors
8.4 Others
9. Ovarian Cancer Drugs Market – Revenue Analysis (USD Million) – By Distribution Channel, 2021-2031
9.1 Overview
9.2 Hospital Pharmacies
9.3 Retail Pharmacies
9.4 Others
10. Ovarian Cancer Drugs Market - Revenue Analysis (USD Million), 2021-2031 – Geographical Analysis
10.1 North America
10.1.1 North America Ovarian Cancer Drugs Market Overview
10.1.2 North America Ovarian Cancer Drugs Market Revenue and Forecasts to 2031
10.1.3 North America Ovarian Cancer Drugs Market Revenue and Forecasts and Analysis - By Type
10.1.4 North America Ovarian Cancer Drugs Market Revenue and Forecasts and Analysis - By Drug Class
10.1.5 North America Ovarian Cancer Drugs Market Revenue and Forecasts and Analysis - By Distribution Channel
10.1.6 North America Ovarian Cancer Drugs Market Revenue and Forecasts and Analysis - By Countries
10.1.6.1 United States Ovarian Cancer Drugs Market
10.1.6.1.1 United States Ovarian Cancer Drugs Market, by Type
10.1.6.1.2 United States Ovarian Cancer Drugs Market, by Drug Class
10.1.6.1.3 United States Ovarian Cancer Drugs Market, by Distribution Channel
10.1.6.2 Canada Ovarian Cancer Drugs Market
10.1.6.2.1 Canada Ovarian Cancer Drugs Market, by Type
10.1.6.2.2 Canada Ovarian Cancer Drugs Market, by Drug Class
10.1.6.2.3 Canada Ovarian Cancer Drugs Market, by Distribution Channel
10.1.6.3 Mexico Ovarian Cancer Drugs Market
10.1.6.3.1 Mexico Ovarian Cancer Drugs Market, by Type
10.1.6.3.2 Mexico Ovarian Cancer Drugs Market, by Drug Class
10.1.6.3.3 Mexico Ovarian Cancer Drugs Market, by Distribution Channel
Note - Similar analysis would be provided for below mentioned regions/countries
10.2 Europe
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 Spain
10.2.5 United Kingdom
10.2.6 Rest of Europe
10.3 Asia-Pacific
10.3.1 Australia
10.3.2 China
10.3.3 India
10.3.4 Japan
10.3.5 South Korea
10.3.6 Rest of Asia-Pacific
10.4 Middle East and Africa
10.4.1 South Africa
10.4.2 Saudi Arabia
10.4.3 U.A.E
10.4.4 Rest of Middle East and Africa
10.5 South and Central America
10.5.1 Brazil
10.5.2 Argentina
10.5.3 Rest of South and Central America
11. Industry Landscape
11.1 Mergers and Acquisitions
11.2 Agreements, Collaborations, Joint Ventures
11.3 New Product Launches
11.4 Expansions and Other Strategic Developments
12. Competitive Landscape
12.1 Heat Map Analysis by Key Players
12.2 Company Positioning and Concentration
13. Ovarian Cancer Drugs Market - Key Company Profiles
13.1 AbbVie Inc
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
Note - Similar information would be provided for below list of companies
13.2 AstraZeneca
13.3 F. Hoffmann-La Roche Ltd
13.4 Pfizer, Inc.
13.5 Merck and Co., Inc.
13.6 ImmunoGen, Inc
13.7 CLOVIS ONCOLOGY
13.8 Boehringer Ingelheim International GmbH
13.9 GlaxoSmithKline, Plc
13.10 Amgen Inc
14. Appendix
14.1 Glossary
14.2 About The Insight Partners
14.3 Market Intelligence Cloud
The List of Companies - Ovarian Cancer Drugs Market
- Elli Lilly
- AstraZeneca
- GSK
- Zielab
- ImmunoGen
- GeneTech (Roche)
- Vivesto
- Allarity Therapeutics, Inc.
- Aeterna Zentaris
- Luye Pharma
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For